PRISM aims to operationalise readiness as a core execution variable.

As trials expand into new geographies and decentralized models mature, sponsors are confronting a core operational challenge in 2026: how to scale global execution while reducing system complexity and ...

We designed the platform so business leaders and their teams can think clearly, act decisively, and stay accountable ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...

From research to enrollment to monitoring, Avenio AI embraced by 30+ BioPharma teams is powering smarter, faster, secure, and compliant trial execution. Rare bottom-up momentum seen as clinicians and ...